<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713410</url>
  </required_header>
  <id_info>
    <org_study_id>No.F.1-1/2015/ERB/SZABMU/465</org_study_id>
    <nct_id>NCT04713410</nct_id>
  </id_info>
  <brief_title>Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome</brief_title>
  <official_title>Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome: A Randomized Control Trial at Children Hospital, Pakistan Institute of Medical Sciences, Islamabad</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaheed Zulfiqar Ali Bhutto Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaheed Zulfiqar Ali Bhutto Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time&#xD;
      will be divided into two groups. One group will be given steroids for 12 weeks and other&#xD;
      group will receive steroid for 20 weeks. During the 1 years after completion of steroid&#xD;
      course patients will be monitor for the episodes of relapse in both group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time,&#xD;
      at Pakistan Institute of Medical Sciences, Islamabad, from December 2020 to December 2022&#xD;
      will be included in the study.&#xD;
&#xD;
      Sample size was calculated by using WHO sample size calculator keeping level of significance&#xD;
      5%, power of test 90%, P1 21.6%7 and P2 59.3%8. The sample size is turned out to be 34&#xD;
      patients in each group with total of 68 patients.&#xD;
&#xD;
      The patients fulfilling the inclusion criteria will be registered at our nephrology clinic.&#xD;
      Patients' bio data along with history and examination will be recorded on a proforma. They&#xD;
      will be divided in two groups designated as A and B. Group A will receive steroid for 12&#xD;
      weeks and group B for 20 weeks. For group A regimen will be to administer prednisolone as a&#xD;
      single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day for another 6&#xD;
      weeks and then stop. For group B prednisolone will be given as a single dose of 60 mg/m2 once&#xD;
      daily for 6 weeks, then 40 mg/m2 on alternate day for another 6 weeks with tapering of 25% of&#xD;
      alternate day dose fortnightly. Outcome will be measured in terms of number of relapses in&#xD;
      the subsequent 1 years after stopping steroids.&#xD;
&#xD;
      For treatment of relapse Prednisolone will be given in the dose of 60 mg/m2 once daily till&#xD;
      urine protein is negative or trace for 3 consecutive days, then 40 mg/m2 on alternate day for&#xD;
      1 month then stop. In case of frequent relapses and steroid dependent cases, relapses will be&#xD;
      treated as follows; prednisolone 60 mg/m2 on alternate day till urine protein will be&#xD;
      negative for 5days then 40 mg/m2 on alternate day for 1 month then with tapering at the rate&#xD;
      of 5 mg fortnightly.&#xD;
&#xD;
      Children with congenital and infantile nephrotic syndrome, persistent hypertension, gross&#xD;
      haematuria, family history of nephrotic syndrome and age below 1 year and above 8 years will&#xD;
      be excluded from study.&#xD;
&#xD;
      After approval of study from ethical review board, informed consent will be taken from&#xD;
      parents. The data obtained will be analyzed using SPSS version 20. The t test will be applied&#xD;
      for comparison of mean and chi sqare test for comparison of percentages. The p value less&#xD;
      than .05 will be taken as significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">September 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse rete</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Steroid-Sensitive Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Steroids will be given for short duration of time i-e 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Steroid will be given for longer duration i-e 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 1 to 8 years of age,&#xD;
&#xD;
          -  Diagnose with nephrotic syndrome for the first time&#xD;
&#xD;
          -  Steroid sensitive nephrotic syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Steroid resistant nephrotic syndrome&#xD;
&#xD;
          -  Steroid dependent nephrotic syndrome&#xD;
&#xD;
          -  Syndromic Children&#xD;
&#xD;
          -  Children with other co morbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pakistan Institute of Medical Sciences</name>
      <address>
        <city>Islamabad</city>
        <state>Capital</state>
        <zip>44000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nighat Haider, FCPS</last_name>
      <phone>03212125768</phone>
      <email>nighathaider@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jai Krishin, FCPS</last_name>
      <phone>03335094933</phone>
      <email>jkrishin@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaheed Zulfiqar Ali Bhutto Medical University</investigator_affiliation>
    <investigator_full_name>Dr Nighat Haider</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Nephrotic Syndrome, steroid response, relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

